Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Asian Currencies Strengthen as Indian Rupee and Australian Dollar Rally 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
India Budget 2025 Highlights Manufacturing Push but Falls Short of Market Expectations 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Taiwan Urges Stronger Trade Ties With Fellow Democracies, Rejects Economic Dependence on China 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
China and Uruguay Strengthen Strategic Partnership Amid Shifting Global Order 
RBA Raises Interest Rates by 25 Basis Points as Inflation Pressures Persist 
Drugmakers including Pfizer Inc, GlaxoSmithKline PLC , Bristol Myers Squibb, AstraZeneca PLC and Sanofi SA will raise prices in the US on over 350 unique drugs in early January.
The increases are in preparation for the Inflation Reduction Act (IRA), which allows the government's Medicare health program to negotiate prices for some drugs starting in 2026.
The pharmaceutical industry is also dealing with inflation and supply chain constraints that increased manufacturing costs.
The price hikes are based on list prices, which do not account for other discounts or rebates to pharmacy benefit managers.
According to data released by 46brooklyn, a drug pricing non-profit affiliated with 3 Axis, drugmakers increased prices on more than 1,400 pharmaceuticals in 2022. Since 2015, there have been the most rises.
According to Antonio Ciaccia, president of 3 Axis, drugmakers have concentrated on releasing their medications at higher prices due to the concentration on annual price hikes.
More drug prices are likely to be announced over the course of January - historically the biggest month for drugmakers to raise prices.
Pfizer has so far disclosed the biggest price hikes, with 89 different prescription names seeing a rise in price in addition to an extra 10 drug brands at its Hospira division.
Then came GSK, which has already announced hikes for 26 different medications, including nearly a 7% rise for its well-known shingles vaccine Shingrix.
